USNANYSEMedicinal Chemicals & Botanical ProductsFiscal year ends January 3
USANA HEALTH SCIENCES INC
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 13, 2026
$14.89−0.65 (-4.18%)
Close on Oct 19, 2026
- Market cap
- $275.26M
- P/E (TTM)
- –
- Dividend yield
- –
USANA HEALTH SCIENCES INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Core Nutritional | $775.45M | $845.79M | $915.21M | – | – | – | – | – | – | – | 83.8% | -8.3% |
| Hiya | $131.97M | $1.97M | – | – | – | – | – | – | – | – | 14.3% | +6599.0% |
| Other | $17.83M | $6.74M | $5.80M | $3.56M | $0 | $0 | – | – | – | – | 1.9% | +164.4% |
| Direct selling | – | $845.79M | $915.21M | $995.04M | $1.19B | $1.13B | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Core Nutritional | $40.51M | $70.78M | $96.35M | – | – | – | – | – | – | – | -42.8% |
| Hiya | $3.41M | $146.00K | – | – | – | – | – | – | – | – | +2232.9% |
| Other | -$6.48M | -$4.60M | -$3.28M | -$1.88M | – | – | – | – | – | – | +40.9% |
| Direct selling | – | $70.78M | $96.35M | $109.50M | – | – | – | – | – | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia Pacific total | $627.16M | $682.99M | $740.44M | $801.92M | $963.19M | $915.02M | $852.27M | $956.58M | $810.44M | $754.45M | 67.8% | -8.2% |
| Greater China | $424.54M | $457.98M | $475.10M | $502.49M | $563.47M | $530.51M | $536.00M | $654.39M | $546.78M | $502.30M | 45.9% | -7.3% |
| China | $381.82M | $413.47M | $427.27M | $453.13M | $506.10M | $470.18M | $471.17M | $586.52M | $482.97M | $437.39M | 41.3% | -7.7% |
| Americas and Europe | $298.09M | $171.52M | $180.58M | $196.69M | $223.27M | $219.62M | $208.64M | $232.67M | $236.82M | $251.64M | 32.2% | +73.8% |
| United States | $224.89M | $91.80M | $95.91M | $106.09M | $125.84M | $107.32M | $105.11M | $116.30M | $121.06M | $130.43M | 24.3% | +145.0% |
| Southeast Asia Pacific | $132.00M | $146.80M | $163.89M | $190.48M | $269.80M | $269.56M | $220.09M | $225.47M | – | – | 14.3% | -10.1% |
| North Asia | $70.63M | $78.21M | $101.45M | $108.95M | $129.92M | $114.96M | $96.19M | $76.72M | $58.38M | $46.02M | 7.6% | -9.7% |
| South Korea | $68.86M | $76.45M | $99.11M | $106.39M | $110.38M | $110.81M | $92.92M | – | – | – | 7.4% | -9.9% |
| Southeast Asia Pacific [Member] | – | – | – | – | – | – | $220.09M | $225.47M | $205.29M | $206.12M | – | – |
From the segment and revenue-disaggregation notes of Usana Health Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.